{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36893122", "DateCompleted": {"Year": "2023", "Month": "03", "Day": "13"}, "DateRevised": {"Year": "2023", "Month": "04", "Day": "20"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "03", "Day": "09"}], "Language": ["eng"], "ELocationID": ["e0282586", "10.1371/journal.pone.0282586"], "Journal": {"ISSN": "1932-6203", "JournalIssue": {"Volume": "18", "Issue": "3", "PubDate": {"Year": "2023"}}, "Title": "PloS one", "ISOAbbreviation": "PLoS One"}, "ArticleTitle": "Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach.", "Pagination": {"StartPage": "e0282586", "MedlinePgn": "e0282586"}, "Abstract": {"AbstractText": ["A new semisynthetic derivative of the natural alkaloid, theobromine, has been designed as a lead antiangiogenic compound targeting the EGFR protein. The designed compound is an (m-tolyl)acetamide theobromine derivative, (T-1-MTA). Molecular Docking studies have shown a great potential for T-1-MTA to bind to EGFR. MD studies (100 ns) verified the proposed binding. By MM-GBSA analysis, the exact binding with optimal energy of T-1-MTA was also identified. Then, DFT calculations were performed to identify the stability, reactivity, electrostatic potential, and total electron density of T-1-MTA. Furthermore, ADMET analysis indicated the T-1-MTA's general likeness and safety. Accordingly, T-1-MTA has been synthesized to be examined in vitro. Intriguingly, T-1-MTA inhibited the EGFR protein with an IC50 value of 22.89 nM and demonstrated cytotoxic activities against the two cancer cell lines, A549, and HCT-116, with IC50 values of 22.49, and 24.97 \u03bcM, respectively. Interestingly, T-1-MTA's IC50 against the normal cell lines, WI-38, was very high (55.14 \u03bcM) indicating high selectivity degrees of 2.4 and 2.2, respectively. Furthermore, the flow cytometry analysis of A549 treated with T-1-MTA showed significantly increased ratios of early apoptosis (from 0.07% to 21.24%) as well as late apoptosis (from 0.73% to 37.97%)."], "CopyrightInformation": "Copyright: \u00a9 2023 Eissa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy (Boys), Pharmaceutical Medicinal Chemistry & Drug Design Department, Al-Azhar University, Cairo, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy (Boys), Pharmaceutical Medicinal Chemistry & Drug Design Department, Al-Azhar University, Cairo, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0003-4497-5013"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Science, Chemistry Department, New Valley University, El-Kharja, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Science, Biophysics Department, Cairo University. Cairo, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": ["0000-0001-9202-1754"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy (Boys), Pharmaceutical Medicinal Chemistry & Drug Design Department, Al-Azhar University, Cairo, Egypt."}], "LastName": "Alesawy", "ForeName": "Mohamed S", "Initials": "MS"}, {"Identifier": ["0000-0003-0893-6703"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy (Boys), Pharmaceutical Medicinal Chemistry & Drug Design Department, Al-Azhar University, Cairo, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy (Boys), Pharmacognosy and Medicinal Plants Department, Al-Azhar University, Cairo, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "PLoS One", "NlmUniqueID": "101285081", "ISSNLinking": "1932-6203"}, "ChemicalList": [{"RegistryNumber": "OBD445WZ5P", "NameOfSubstance": "Theobromine"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Theobromine"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Drug Discovery"}, {"QualifierName": ["metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}], "CoiStatement": "The authors have declared that no competing interests exist."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abd El-Mageed M.M., Eissa A.A., Farag A.E.-S., Osman E.E.A., Design and synthesis of novel furan, furo [2, 3-d] pyrimidine and furo [3, 2-e][1, 2, 4] triazolo [1, 5-c] pyrimidine derivatives as potential VEGFR-2 inhibitors, Bioorganic Chemistry (2021) 105336. doi: 10.1016/j.bioorg.2021.105336", "ArticleIdList": ["10.1016/j.bioorg.2021.105336", "34530235"]}, {"Citation": "Chaudhari P., Bari S., Surana S., Shirkhedkar A., Wakode S., Shelar S., et al S. Ghodke, Logical synthetic strategies and structure-activity relationship of indolin-2-one hybrids as small molecule anticancer agents: An Overview, Journal of Molecular Structure (2021) 131280."}, {"Citation": "El-Dash Y., Elzayat E., Abdou A.M., Hassan R.A., Novel thienopyrimidine-aminothiazole hybrids: design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition, Bioorganic Chemistry 114 (2021) 105137. doi: 10.1016/j.bioorg.2021.105137", "ArticleIdList": ["10.1016/j.bioorg.2021.105137", "34237644"]}, {"Citation": "Nicholson R.I., Gee J.M.W., Harper M.E., EGFR and cancer prognosis, European journal of cancer 37 (2001) 9\u201315.", "ArticleIdList": ["11597399"]}, {"Citation": "Spano J.-P., Lagorce C., Atlan D., Milano G., Domont J., Benamouzig R., et al.. Morere, Impact of EGFR expression on colorectal cancer patient prognosis and survival, Annals of oncology 16(1) (2005) 102\u2013108.", "ArticleIdList": ["15598946"]}, {"Citation": "Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., et al.. Salomon, Epidermal growth factor receptor (EGFR) signaling in cancer, Gene 366(1) (2006) 2\u201316.", "ArticleIdList": ["16377102"]}, {"Citation": "Ayati A., Moghimi S., Salarinejad S., Safavi M., Pouramiri B., A.J.B. c. Foroumadi, A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy, 99 (2020) 103811.", "ArticleIdList": ["32278207"]}, {"Citation": "Eldehna W.M., El Hassab M.A., Elsayed Z.M., Al-Warhi T., Elkady H., Abo-Ashour M.F., et al., Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4, 5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity, Scientific reports 12(1) (2022) 1\u201313.", "ArticleIdList": ["PMC9329325", "35896557"]}, {"Citation": "Metwaly A.M., Ghoneim M.M., Eissa I.H., Elsehemy I.A., Mostafa A.E., Hegazy M.M., et al., Traditional ancient Egyptian medicine: a review, Saudi Journal of Biological Sciences (2021) 5823\u20135832. doi: 10.1016/j.sjbs.2021.06.044", "ArticleIdList": ["10.1016/j.sjbs.2021.06.044", "PMC8459052", "34588897"]}, {"Citation": "Han X., Yang Y., Metwaly A.M., Xue Y., Shi Y., Dou D., The Chinese herbal formulae (Yitangkang) exerts an antidiabetic effect through the regulation of substance metabolism and energy metabolism in type 2 diabetic rats, Journal of ethnopharmacology 239 (2019) 111942. doi: 10.1016/j.jep.2019.111942", "ArticleIdList": ["10.1016/j.jep.2019.111942", "31075380"]}, {"Citation": "Newman D.J., Cragg G.M., Natural products as sources of new drugs from 1981 to 2014, Journal of Natural Products 79(3) (2016) 629\u2013661. doi: 10.1021/acs.jnatprod.5b01055", "ArticleIdList": ["10.1021/acs.jnatprod.5b01055", "26852623"]}, {"Citation": "Barcz E., Sommer E., Janik P., Marianowski L., Skopinska-Rozewska E., Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells, Oncology reports 7(6) (2000) 1285\u20131376. doi: 10.3892/or.7.6.1285", "ArticleIdList": ["10.3892/or.7.6.1285", "11032931"]}, {"Citation": "Kakuyamanee Iwazaki A., Sadzuka Y., Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity, Current drug metabolism 2(4) (2001) 379\u2013395. doi: 10.2174/1389200013338270", "ArticleIdList": ["10.2174/1389200013338270", "11766989"]}, {"Citation": "Sultani H.N., Ghazal R.A., Hayallah A.M., Abdulrahman L.K., Abu\u2010Hammour K., AbuHammad S., et al M.O., Inhibitory effects of new mercapto xanthine derivatives in human mcf7 and k562 cancer cell lines, Journal of Heterocyclic Chemistry 54(1) (2017) 450\u2013456."}, {"Citation": "Woskresensky A., Ueber das Theobromin, Justus Liebigs Annalen der Chemie 41(1) (1842) 125\u2013127."}, {"Citation": "A.J.J.L.A.d.C. Woskresensky, Ueber das Theobromin, 41(1) (1842) 125\u2013127."}, {"Citation": "Fredholm B.B., Smit H.J., Theobromine and the pharmacology of cocoa, Methylxanthines (2011) 201\u2013234.", "ArticleIdList": ["20859797"]}, {"Citation": "Sugimoto N., Miwa S., Hitomi Y., Nakamura H., Tsuchiya H., Yachie A., Theobromine, the primary methylxanthine found in Theobroma cacao, prevents malignant glioblastoma proliferation by negatively regulating phosphodiesterase-4, extracellular signal-regulated kinase, Akt/mammalian target of rapamycin kinase, and nuclear factor-kappa B, Nutrition and cancer 66(3) (2014) 419\u2013423. doi: 10.1080/01635581.2013.877497", "ArticleIdList": ["10.1080/01635581.2013.877497", "24547961"]}, {"Citation": "Gil M., Skopi\u0144ska-R\u00f3zewska E., Radomska D., Demkow U., Skurzak H., Rochowska M., et al., Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice, Folia Biologica 39(2) (1993) 63\u201368.", "ArticleIdList": ["7504997"]}, {"Citation": "Barcz E., Sommer E., Sokolnicka I., Gawrychowski K., Roszkowska-Purska K., Janik P., et al., The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells, Oncology reports 5(2) (1998) 517\u2013537. doi: 10.3892/or.5.2.517", "ArticleIdList": ["10.3892/or.5.2.517", "9468592"]}, {"Citation": "da Rosa R., Schenkel E.P., Bernardes L.S.C., Semisynthetic and newly designed derivatives based on natural chemical scaffolds: moving beyond natural products to fight Trypanosoma cruzi, Phytochemistry Reviews 19(1) (2020) 105\u2013122."}, {"Citation": "Belal A., Abdel Gawad N.M., Mehany A.B., Abourehab M.A., Elkady H., Al\u2010Karmalawy A.A., Ismael A.S., Design, synthesis and molecular docking of new fused 1 H-pyrroles, pyrrolo [3, 2-d] pyrimidines and pyrrolo [3, 2-e][1, 4] diazepine derivatives as potent EGFR/CDK2 inhibitors, Journal of Enzyme Inhibition and Medicinal Chemistry 37(1) (2022) 1884\u20131902. doi: 10.1080/14756366.2022.2096019", "ArticleIdList": ["10.1080/14756366.2022.2096019", "PMC9272933", "35801486"]}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., El-Deeb N.M., Kenawy A.M., Elkaeed E.B., et al., Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies, Journal of Enzyme Inhibition and Medicinal Chemistry 37(1) (2022) 1903\u20131917. doi: 10.1080/14756366.2022.2085693", "ArticleIdList": ["10.1080/14756366.2022.2085693", "PMC9272924", "35801403"]}, {"Citation": "Elkaeed E.B., Youssef F.S., Eissa I.H., Elkady H., Alsfouk A.A., Ashour M.L., et al., Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease, International Journal of Molecular Sciences 23(13) (2022) 6912. doi: 10.3390/ijms23136912", "ArticleIdList": ["10.3390/ijms23136912", "PMC9266348", "35805916"]}, {"Citation": "Belal A., Elanany M.A., Santali E.Y., Al-Karmalawy A.A., Aboelez M.O., Amin A.H., et al., Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management, Molecules 27(11) (2022) 3584. doi: 10.3390/molecules27113584", "ArticleIdList": ["10.3390/molecules27113584", "PMC9182209", "35684529"]}, {"Citation": "Taghour M.S., Mahdy H.A., Gomaa M.H., Aglan A., Eldeib M.G., Elwan A., et al., Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation, Journal of Enzyme Inhibition and Medicinal Chemistry 37(1) (2022) 2063\u20132077. doi: 10.1080/14756366.2022.2103552", "ArticleIdList": ["10.1080/14756366.2022.2103552", "PMC9327782", "35875937"]}, {"Citation": "Suleimen Y.M., Jose R.A., Suleimen R.N., Ishmuratova M.Y., Toppet S., Dehaen W., et al A.A., Isolation and In Silico SARS-CoV-2 Main Protease Inhibition Potential of Jusan Coumarin, a New Dicoumarin from Artemisia glauca, Molecules 27(7) (2022) 2281. doi: 10.3390/molecules27072281", "ArticleIdList": ["10.3390/molecules27072281", "PMC9000794", "35408682"]}, {"Citation": "Eissa I.H., Khalifa M.M., Elkaeed E.B., Hafez E.E., Alsfouk A.A., Metwaly A.M., In Silico Exploration of Potential Natural Inhibitors against SARS-Cov-2 nsp10, Molecules 26(20) (2021) 6151. doi: 10.3390/molecules26206151", "ArticleIdList": ["10.3390/molecules26206151", "PMC8539059", "34684735"]}, {"Citation": "Elkaeed E.B., Elkady H., Belal A., Alsfouk B.A., Ibrahim T.H., Abdelmoaty M., et al., Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs, Processes 10(3) (2022) 530."}, {"Citation": "Suleimen Y.M., Jose R.A., Suleimen R.N., Arenz C., Ishmuratova M., Toppet S., et al.. Eissa, Isolation and In Silico Anti-SARS-CoV-2 Papain-Like Protease Potentialities of Two Rare 2-Phenoxychromone Derivatives from Artemisia spp, Molecules 27(4) (2022) 1216.", "ArticleIdList": ["PMC8879996", "35209006"]}, {"Citation": "Bonomi P., Erlotinib: a new therapeutic approach for non-small cell lung cancer, Expert opinion on investigational drugs 12(8) (2003) 1395\u20131401. doi: 10.1517/13543784.12.8.1395", "ArticleIdList": ["10.1517/13543784.12.8.1395", "12882624"]}, {"Citation": "Nossier E.S., Alasfoury R.A., Hagras M., El-Manawaty M., Sayed S.M., Ibrahim I.M., et al H., Modified pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation, Journal of Molecular Structure (2022) 133971.", "ArticleIdList": ["PMC9291687", "35821615"]}, {"Citation": "J\u00e4nne P.A., Yang J.C.-H., Kim D.-W., Planchard D., Ohe Y., Ramalingam S.S., et al., AZD9291 in EGFR inhibitor\u2013resistant non\u2013small-cell lung cancer, New England Journal of Medicine 372(18) (2015) 1689\u20131699. doi: 10.1056/NEJMoa1411817", "ArticleIdList": ["10.1056/NEJMoa1411817", "25923549"]}, {"Citation": "Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., et al., Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino) pyrazolo [3, 4-d] pyrimidines, Journal of medicinal chemistry 40(22) (1997) 3601\u20133616. doi: 10.1021/jm970124v", "ArticleIdList": ["10.1021/jm970124v", "9357527"]}, {"Citation": "Ducray R., Ballard P., Barlaam B.C., Hickinson M.D., Kettle J.G., Ogilvie D.J., et al., Novel 3-alkoxy-1H-pyrazolo [3, 4-d] pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors, Bioorganic & medicinal chemistry letters 18(3) (2008) 959\u2013962. doi: 10.1016/j.bmcl.2007.12.035", "ArticleIdList": ["10.1016/j.bmcl.2007.12.035", "18182285"]}, {"Citation": "Elmetwally S.A., Saied K.F., Eissa I.H., Elkaeed E.B., Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers, Bioorganic chemistry 88 (2019) 102944. doi: 10.1016/j.bioorg.2019.102944", "ArticleIdList": ["10.1016/j.bioorg.2019.102944", "31051400"]}, {"Citation": "Zhao Z., Wu H., Wang L., Liu Y., Knapp S., Liu Q., et al., Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?, ACS chemical biology 9(6) (2014) 1230\u20131241. doi: 10.1021/cb500129t", "ArticleIdList": ["10.1021/cb500129t", "PMC4068218", "24730530"]}, {"Citation": "Furet P., Caravatti G., Lydon N., Priestle J.P., Sowadski J.M., Trinks U., Traxler P., Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411, Journal of Computer-Aided Molecular Design 9(6) (1995) 465\u2013472. doi: 10.1007/BF00124317", "ArticleIdList": ["10.1007/BF00124317", "8789188"]}, {"Citation": "Mowafy S., Galanis A., Doctor Z.M., Paranal R.M., Lasheen D.S., Farag N.A., et al., Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives, Biorg. Med. Chem. 24(16) (2016) 3501\u20133512.", "ArticleIdList": ["27288180"]}, {"Citation": "Gandin V., Ferrarese A., Dalla Via M., Marzano C., Chilin A., Marzaro G., Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N\u2019-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily, Scientific reports 5 (2015) 16750. doi: 10.1038/srep16750", "ArticleIdList": ["10.1038/srep16750", "PMC4645160", "26568452"]}, {"Citation": "Liu Y., Gray N.S., Rational design of inhibitors that bind to inactive kinase conformations, Nature Chemical Biology 2(7) (2006) 358\u2013364. doi: 10.1038/nchembio799", "ArticleIdList": ["10.1038/nchembio799", "16783341"]}, {"Citation": "Gaber A.A., Bayoumi A.H., El-Morsy A.M., Sherbiny F.F., Mehany A.B., Eissa I.H., Design, synthesis and anticancer evaluation of 1H-pyrazolo [3, 4-d] pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers, Bioorganic chemistry 80 (2018) 375\u2013395. doi: 10.1016/j.bioorg.2018.06.017", "ArticleIdList": ["10.1016/j.bioorg.2018.06.017", "29986185"]}, {"Citation": "Nasser A.A., Eissa I.H., Oun M.R., El-Zahabi M.A., Taghour M.S., Belal A., et al., Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M, Organic & biomolecular chemistry 18(38) (2020) 7608\u20137634. doi: 10.1039/d0ob01557a", "ArticleIdList": ["10.1039/d0ob01557a", "32959865"]}, {"Citation": "Elzahabi H.S., Nossier E.S., Alasfoury R.A., El-Manawaty M., Sayed S.M., Elkaeed E.B., et al., Design, synthesis, and anti-cancer evaluation of new pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers, Journal of Enzyme Inhibition and Medicinal Chemistry 37(1) (2022) 1053\u20131076. doi: 10.1080/14756366.2022.2062752", "ArticleIdList": ["10.1080/14756366.2022.2062752", "PMC9291687", "35821615"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Alsfouk A.A., Husein D.Z., Ibrahim I.M., et al., New anticancer theobromine derivative targeting egfrwt and egfrt790m: Design, semi-synthesis, in silico, and in vitro anticancer studies, Molecules 27(18) (2022) 5859. doi: 10.3390/molecules27185859", "ArticleIdList": ["10.3390/molecules27185859", "PMC9500845", "36144596"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Alsfouk A.A., Husein D.Z., Ibrahim I.M., et al A New Theobromine-Based EGFRWT and EGFRT790M Inhibitor and Apoptosis Inducer: Design, Semi-Synthesis, Docking, DFT, MD Simulations, and In Vitro Studies, Processes 10(11) (2022) 2290."}, {"Citation": "Husein D.Z., Hassanien R., Khamis M.J.R.A., Cadmium oxide nanoparticles/graphene composite: synthesis, theoretical insights into reactivity and adsorption study, 11(43) (2021) 27027\u201327041. doi: 10.1039/d1ra04754j", "ArticleIdList": ["10.1039/d1ra04754j", "PMC9037664", "35480026"]}, {"Citation": "Hanee U., Rahman M., Matin M.M., Synthesis PASS, In Silico ADMET and thermodynamic studies of some galactopyranoside esters, Physical Chemistry Research 9(4) (2021) 591\u2013603."}, {"Citation": "Wang T., Husein D.Z.J.E.S., Research P., Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: disposing of waste with waste, (2022) 1\u201328.", "ArticleIdList": ["35460480"]}, {"Citation": "Ferreira L.L., Andricopulo A.D., ADMET modeling approaches in drug discovery, Drug discovery today 24(5) (2019) 1157\u20131165. doi: 10.1016/j.drudis.2019.03.015", "ArticleIdList": ["10.1016/j.drudis.2019.03.015", "30890362"]}, {"Citation": "Norinder U., Bergstr\u00f6m C.A., Prediction of ADMET properties, ChemMedChem: Chemistry Enabling Drug Discovery 1(9) (2006) 920\u2013937.", "ArticleIdList": ["16952133"]}, {"Citation": "Dearden J.C., In silico prediction of drug toxicity, Journal of computer-aided molecular design 17(2) (2003) 119\u2013127. doi: 10.1023/a:1025361621494", "ArticleIdList": ["10.1023/a:1025361621494", "13677480"]}, {"Citation": "Idakwo G., Luttrell J., Chen M., Hong H., Zhou Z., Gong P., Zhang C., A review on machine learning methods for in silico toxicity prediction, Journal of Environmental Science and Health, Part C 36(4) (2018) 169\u2013191. doi: 10.1080/10590501.2018.1537118", "ArticleIdList": ["10.1080/10590501.2018.1537118", "30628866"]}, {"Citation": "Kruhlak N., Benz R., Zhou H., Colatsky T., (Q) SAR modeling and safety assessment in regulatory review, Clinical Pharmacology & Therapeutics 91(3) (2012) 529\u2013534.", "ArticleIdList": ["22258468"]}, {"Citation": "Elwan A., Abdallah A.E., Mahdy H.A., Dahab M.A., Taghour M.S., Elkaeed E.B., et al.. Alsfouk, Modified benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, and anti-proliferative evaluation, Molecules 27(15) (2022) 5047.", "ArticleIdList": ["PMC9370530", "35956997"]}, {"Citation": "Nossier E.S., Alasfoury R.A., Hagras M., El-Manawaty M., Sayed S.M., Ibrahim I.M., et al., Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation, Journal of Molecular Structure (2022) 133971.", "ArticleIdList": ["PMC9291687", "35821615"]}, {"Citation": "Alsaif N.A., Taghour M.S., Alanazi M.M., Obaidullah A.J., Al-Mehizia A.A., Alanazi M.M., et al.. Elkady, Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3\u2019, 4\u2019-c] quinoxaline derivatives as anticancer agents and apoptosis inducers, Journal of enzyme inhibition and medicinal chemistry 36(1) (2021) 1093\u20131114.", "ArticleIdList": ["PMC8168755", "34056992"]}, {"Citation": "Alanazi M.M., Eissa I.H., Alsaif N.A., Obaidullah A.J., Alanazi W.A., Alasmari A.F., et al., Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers, Journal of Enzyme Inhibition and Medicinal Chemistry 36(1) (2021) 1760\u20131782. doi: 10.1080/14756366.2021.1956488", "ArticleIdList": ["10.1080/14756366.2021.1956488", "PMC8344243", "34340610"]}, {"Citation": "Elkaeed E.B., Eissa I.H., Elkady H., Abdelalim A., Alqaisi A.M., Alsfouk A.A., et al A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease, International Journal of Molecular Sciences 23(15) (2022) 8407.", "ArticleIdList": ["PMC9369012", "35955547"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Gobaara I.M.M., Alsfouk B.A., Husein D.Z., et al., Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects, Molecules 27(14) (2022) 4606. doi: 10.3390/molecules27144606", "ArticleIdList": ["10.3390/molecules27144606", "PMC9317904", "35889478"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "1", "Day": "19"}, {"Year": "2023", "Month": "2", "Day": "18"}, {"Year": "2023", "Month": "3", "Day": "9", "Hour": "13", "Minute": "42"}, {"Year": "2023", "Month": "3", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "3", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "3", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["36893122", "PMC9997933", "10.1371/journal.pone.0282586", "PONE-D-23-01754"]}}], "PubmedBookArticle": []}